PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors
Journal of Controlled Release · 2025-03 · 379 · 890-905
DOI: 10.1016/j.jconrel.2025.01.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Cristian Rosales-Barrios und 6 weiteren Autor:innen. Beteiligte Einrichtung: Asymmetric Synthesis and Functional Nanosystems Group (Art&Fun), Institute of Chemical Research (IIQ), CSIC-University of Seville, C/ Américo Vespuci…. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Consejo Superior de Investigaciones Científicas, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía.
Abstract (Originalsprache)
In this study, we present the first comparative analysis of active and passive drug delivery systems for docetaxel (DTX) in prostate cancer using supramolecular self-assembled micellar nanovectors. Specifically, we developed two novel micelles based on polydiacetylenic amphiphiles (PDA) for passive and active targeting. The active targeting micelles were designed with a prostate-specific membrane antigen (PSMA) ligand, ACUPA, to facilitate recognition by PSMA-positive cancer cells. These PDA-based micelles feature a well-defined structure with a hydrophobic PDA core and a surface functionalized with PEG, and for active targeting, ACUPA. Our micelles demonstrated excellent encapsulation capacity, significantly improving DTX solubility in water, a crucial factor for clinical drug use. In vitro studies confirmed the safety and cytotoxic profiles of both systems, with ACUPA-functionalized micelles showing notable internalization into PSMA-positive LNCaP cells, mediated through the PSMA-ACUPA interaction. In vivo imaging revealed preferential accumulation of ACUPA-functionalized nanomicelles in LNCaP xenograft tumors, suggesting enhanced retention via specific ACUPA-PSMA interactions and active uptake by LNCaP cells. Notably, Balb/c-Foxn1nu/nu early in vivo studies showed a marked reduction in tumor volume and tumor expression levels of proliferation, cell cycle progression, cell survival and anti-apoptotic markers with DTX-loaded micelles functionalized with ACUPA compared to those without ACUPA. Overall, our studies collect initial evidence regarding the feasibility of supramolecular self-assembly of ACUPA-PDA-based nanomicelles for PSMA-targeted drug chemotherapy delivery developments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asymmetric Synthesis and Functional Nanosystems Group (Art&Fun), Institute of Chemical Research (IIQ), CSIC-University of Seville, C/ Américo Vespucio 49, 41092 Seville, Spain.
- Department of Integrative Pathophysiology and Therapies, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), CSIC-Universidad Pablo de Olavide-Universidad de Sevilla, Av. Americo Vespucio 24, Se…
- Maimónides Institute for Biomedical Research of Córdoba (IMIBIC), University Hospital Reina Sofía (HURS), Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Av. Menéndez Pi…
- Asymmetric Synthesis and Functional Nanosystems Group (Art&Fun), Institute of Chemical Research (IIQ), CSIC-University of Seville, C/ Américo Vespucio 49, 41092 Seville, Spain. Electronic address: khiar@iiq.csic.es.
Förderung
- Ministerio de Ciencia e Innovación
- Consejo Superior de Investigaciones Científicas
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía
- European Social Fund Plus
- Federación Española de Enfermedades Raras
- European Regional Development Fund
- Junta de Andalucía
Zitieren
APA
Rosales-Barrios, C., González-Sánchez, Z. I., Zuliani, A., Jiménez-Vacas, J. M., Luque, R. M., Pozo, D., & Khiar, N. (2025). PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors. Journal of Controlled Release, 379, 890-905. https://doi.org/10.1016/j.jconrel.2025.01.062
Vancouver
Rosales-Barrios C, González-Sánchez ZI, Zuliani A, Jiménez-Vacas JM, Luque RM, Pozo D, et al. PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors. Journal of Controlled Release. 2025;379:890-905. doi:10.1016/j.jconrel.2025.01.062
BibTeX
@article{RosalesBarrios2025,
author = {Rosales-Barrios, Cristian and González-Sánchez, Zaira I and Zuliani, Alessio and Jiménez-Vacas, Juan M and Luque, Raul M and Pozo, David and Khiar, Noureddine},
title = {PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors},
journal = {Journal of Controlled Release},
year = {2025},
volume = {379},
pages = {890--905},
doi = {10.1016/j.jconrel.2025.01.062}
}
EUVIMED